<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2c0284c8-3a82-4bb9-a486-a03fc1491c66"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>GANIRELIX ACETATE INJECTION<br/>250 mcg/0.5 mL<br/>
      <br/>For Subcutaneous Use Only<br/>
      <br/>Rx Only</title>
   <effectiveTime value="20250317"/>
   <setId root="e50888ef-5e66-4b15-bdc3-2f6794f09246"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="675923163" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN LIMITED</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="675485014" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70748-274" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70748-274" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e19b2843-e2ef-4432-bfd0-0050bc38f484"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250317"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70748-274" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ganirelix Acetate</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ganirelix Acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="250" unit="ug"/>
                              <denominator value="0.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="56U7906FQW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GANIRELIX ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IX503L9WN0" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GANIRELIX</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.1" unit="mg"/>
                              <denominator value="0.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="23.5" unit="mg"/>
                              <denominator value="0.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="70748-274-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20240214"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216075" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240214"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="174e7e1f-c7b3-4e0b-a0e7-49f2e8390816"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph ID="ID2">Ganirelix acetate injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix acetate is derived from native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, 8, and 10 to form the following molecular formula of the peptide: N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N<sup>9</sup>,N<sup>10</sup>-diethyl-D-homoarginyl-L-leucyl-N<sup>9</sup>,N<sup>10</sup>-diethyl-L-homoarginyl-L-prolyl-D-alanylamide acetate. The molecular weight for ganirelix acetate is 1570.42 as an anhydrous free base. The structural formula is as follows:</paragraph>
                  <paragraph>Ganirelix Acetate</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID4">Ganirelix acetate injection is supplied as a colorless, sterile, ready-to-use, aqueous solution intended for SUBCUTANEOUS administration only. Each single dose, sterile, prefilled syringe contains 250 mcg/0.5 mL of ganirelix acetate, 0.1 mg glacial acetic acid, 23.5 mg mannitol, and water for injection adjusted to pH 5 with glacial acetic acid, USP and/or sodium hydroxide, NF.</paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="2c0284c8-3a82-4bb9-a486-a03fc1491c66-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="347b701d-59f0-4577-82ff-14b0e9fca955"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph ID="ID6">The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient rises in serum LH. At midcycle, a large increase in GnRH release results in an LH surge. The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. Luteinization results in a rise in serum progesterone with an accompanying decrease in estradiol levels.</paragraph>
                  <paragraph>Ganirelix acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by ganirelix acetate is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix acetate, which is consistent with an antagonist effect. Upon discontinuation of ganirelix acetate, pituitary LH and FSH levels are fully recovered within 48 hours.</paragraph>
               </text>
               <effectiveTime value="20241016"/>
               <component>
                  <section ID="ID7">
                     <id root="445773b8-6c4f-4524-a29d-304570afd8d4"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID8">The pharmacokinetic parameters of single and multiple injections of ganirelix acetate injection in healthy adult females are summarized in Table 1. Steady-state serum concentrations are reached after 3 days of treatment. The pharmacokinetics of ganirelix acetate are dose-proportional in the dose range of 125 to 500 mcg.</paragraph>
                        <table ID="ID9" width="0" styleCode="Noautorules">
                           <caption>  Table 1: Mean (SD) Pharmacokinetic Parameters of 250 mcg of Ganirelix Acetate Following a Single Subcutaneous (SC) Injection (n=15) and Daily SC Injections (n=15) for seven days </caption>
                           <col width="143"/>
                           <col width="83"/>
                           <col width="79"/>
                           <col width="70"/>
                           <col width="81"/>
                           <col width="72"/>
                           <col width="90"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">t<sub>max</sub>  Time to maximum concentration </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">t<sub>½</sub>
                                       <sub/>    Elimination half-life</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">C<sub>max</sub>  Maximum serum concentration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">AUC   Area under the curve; Single dose: AUC<sub>0 to</sub>
                                       <sub/>
                                       <sub>∞</sub>; multiple dose: AUC<sub>0 to 24</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">V<sub>d </sub>     Volume of distribution</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">†         Based on intravenous administration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">CL      Clearance = Dose/AUC<sub>0 to ∞</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">F         Absolute bioavailability</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> t<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> h</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> t<sub>½</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> h</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> ng/mL</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC</content>
                                    <br/>
                                    <content styleCode="bold"> ng•h/mL</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> CL/F</content>
                                    <br/>
                                    <content styleCode="bold"> L/h</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> V<sub>d</sub>/F </content>
                                    <br/>
                                    <content styleCode="bold"> L</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ganirelix Acetate single dose<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.1 (0.3)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12.8 (4.3)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 14.8 (3.2)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 96 (12)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.4 (0.2)<sup>†</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 43.7 (11.4)<sup>†</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ganirelix Acetate multiple dose<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.1 (0.2)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 16.2 (1.6)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11.2 (2.4)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 77.1 (9.8)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3.3 (0.4)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 76.5 (10.3)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID10">
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>Ganirelix Acetate is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing. The mean absolute bioavailability of ganirelix acetate following a single 250 mcg subcutaneous injection to healthy female volunteers is 91.1%.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>The mean (SD) volume of distribution of ganirelix acetate in healthy females following intravenous administration of a single 250-mcg dose is 43.7 (11.4) liters (L). <content styleCode="italics">In vitro </content>protein binding to human plasma is 81.9%.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>Following single-dose intravenous administration of radiolabeled ganirelix acetate to healthy female volunteers, ganirelix acetate is the major compound present in the plasma (50 to 70% of total radioactivity in the plasma) up to 4 hours and urine (17.1 to 18.4% of administered dose) up to 24 hours. Ganirelix acetate is not found in the feces. The 1 to 4 peptide and 1 to 6 peptide of ganirelix acetate are the primary metabolites observed in the feces.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Excretion</content>
                           </content>
                        </paragraph>
                        <paragraph>On average, 97.2% of the total radiolabeled ganirelix acetate dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [<sup>14</sup>C]-ganirelix acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.</paragraph>
                     </text>
                     <effectiveTime value="20241025"/>
                  </section>
               </component>
               <component>
                  <section ID="ID54">
                     <id root="e15ce5cd-3f9f-4c14-815c-5ea4d3cb58ac"/>
                     <title>Special Populations</title>
                     <text>
                        <paragraph ID="ID55">The pharmacokinetics of ganirelix acetate injection have not been determined in special populations such as geriatric, pediatric, renally impaired and hepatically impaired patients (see <content styleCode="bold">
                              <linkHtml href="#ID24">PRECAUTIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Drug-Drug Interactions</content>
                           </content>
                        </paragraph>
                        <paragraph>Formal <content styleCode="italics">in vivo </content>or <content styleCode="italics">in vitro </content>drug-drug interaction studies have not been conducted (see <content styleCode="bold">
                              <linkHtml href="#ID24">PRECAUTIONS</linkHtml>
                           </content>). Since ganirelix acetate can suppress the secretion of pituitary gonadotropins, dose adjustments of exogenous gonadotropins may be necessary when used during controlled ovarian hyperstimulation (COH).</paragraph>
                     </text>
                     <effectiveTime value="20210401"/>
                  </section>
               </component>
               <component>
                  <section ID="ID11">
                     <id root="e2deaaec-65ea-433d-853f-0f7f990638c8"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>Clinical Studies</title>
                     <text>
                        <paragraph ID="ID12">The efficacy of ganirelix acetate injection was established in two adequate and well-controlled clinical studies which included women with normal endocrine and pelvic ultrasound parameters. The studies intended to exclude subjects with polycystic ovary syndrome (PCOS) and subjects with low or no ovarian reserve. One cycle of study medication was administered to each randomized subject. For both studies, the administration of exogenous recombinant FSH [Follistim<sup>®</sup> (follitropin beta for injection)] 150 IU daily was initiated on the morning of Day 2 or 3 of a natural menstrual cycle. Ganirelix acetate injection was administered on the morning of Day 7 or 8 (Day 6 of recombinant FSH administration). The dose of recombinant FSH administered was adjusted according to individual responses starting on the day of initiation of ganirelix acetate. Both recombinant FSH and ganirelix acetate were continued daily until at least three follicles were 17 mm or greater in diameter at which time hCG [Pregnyl<sup>®</sup> (chorionic gonadotropin for injection, USP)] was administered. Following hCG administration, ganirelix acetate and recombinant FSH administration were discontinued. Oocyte retrieval, followed by <content styleCode="italics">in vitro </content>fertilization (IVF) or intracytoplasmic sperm injection (ICSI), was subsequently performed.</paragraph>
                        <paragraph>In a multicenter, double-blind, randomized, dose-finding study, the safety and efficacy of ganirelix acetate injection were evaluated for the prevention of LH surges in women undergoing COH with recombinant FSH. Ganirelix acetate injection doses ranging from 62.5 mcg to 2000 mcg and recombinant FSH were administered to 332 patients undergoing COH for IVF (see Table 2). Median serum LH on the day of hCG administration decreased with increasing doses of ganirelix acetate. Median serum E<sub>2</sub> (17<content styleCode="italics">β</content>-estradiol) on the day of hCG administration was 1475, 1110, and 1160 pg/mL for the 62.5-, 125-, and 250-mcg doses, respectively. Lower peak serum E<sub>2</sub> levels of 823, 703, and 441 pg/mL were seen at higher doses of ganirelix acetate 500, 1000, and 2000 mcg, respectively. The highest pregnancy and implantation rates were achieved with the 250-mcg dose of ganirelix acetate injection as summarized in Table 2.</paragraph>
                        <table ID="ID13" width="100%" styleCode="Noautorules">
                           <caption>  Table 2: Results from the Multicenter, Double-blind, Randomized, Dose-finding Study to Assess the Efficacy of Ganirelix Acetate Injection to Prevent Premature LH Surges in Women Undergoing COH with Recombinant FSH </caption>
                           <col width="24%"/>
                           <col width="12%"/>
                           <col width="11%"/>
                           <col width="13%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="13%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <content styleCode="italics">(Protocol 38602)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td colspan="6" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Daily dose (mcg) of Ganirelix Acetate Injection</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 62.5 mcg</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 125 mcg</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 250 mcg</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 500 mcg</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1000 mcg</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 2000 mcg</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. subjects receiving ganirelix acetate<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 31<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 66<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 70<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 69<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 66<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 30<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. subjects with ET<footnote ID="ID130">ET: Embryo Transfer</footnote>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 27<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 61<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 62<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 54<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 61<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 27<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. of subjects with LH rise ≥ 10 mIU/mL<footnote ID="ID131">Following initiation of ganirelix acetate therapy. Includes subjects who have complied with daily injections</footnote>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Serum LH (mIU/mL) on day of hCG<footnote ID="ID132">Median values</footnote>
                                    <br/> 5<sup>th</sup> to 95<sup>th</sup> percentiles<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 3.6<br/> 0.6 to 19.9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 2.5<br/> 0.6 to 11.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 1.7<br/> &lt; 0.25 to 6.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 1<br/> 0.4 to 4.7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 0.6<br/> &lt; 0.25 to 2.2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 0.3<br/> &lt; 0.25 to 0.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Rrule" align="left"> Serum E<sub>2</sub> (pg/mL) on day of hCG<footnoteRef IDREF="ID132"/>
                                    <br/> 5<sup>th</sup> to 95<sup>th</sup> percentiles<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center"> 1475<br/> 645 to 3720<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center"> 1110<br/> 424 to 3780<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center"> 1160<br/> 384 to 3910<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center"> 823<br/> 279 to 2720<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center"> 703<br/> 284 to 2360<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center"> 441<br/> 166 to 1940<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Vital pregnancy rate<footnote ID="ID133">
                                       <sup/>As evidenced by ultrasound at 5 to 6 weeks following ET</footnote>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule"/>
                                 <td styleCode=" Toprule Botrule Rrule"/>
                                 <td styleCode=" Toprule Botrule Rrule"/>
                                 <td styleCode=" Toprule Botrule Rrule"/>
                                 <td styleCode=" Toprule Botrule Rrule"/>
                                 <td styleCode=" Toprule Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> per attempt, n (%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7 (22.6)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 17 (25.8)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25 (35.7)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8 (11.6)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9 (13.6)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2 (6.7)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> per transfer, n (%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7 (25.9)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 17 (27.9)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25 (40.3)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8 (14.8)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9 (14.8)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2 (7.4)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Implantation rate (%)<footnote ID="ID134">Mean (standard deviation)</footnote>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 14.2 (26.8)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 16.3 (30.5)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 21.9 (30.6)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9 (23.7)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8.5 (21.7)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4.9 (20.1)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID14">Transient LH rises alone were not deleterious to achieving pregnancy with ganirelix acetate at doses of 125 mcg (3/6 subjects) and 250 mcg (1/1 subjects). In addition, none of the subjects with LH rises ≥ 10 mIU/mL had premature luteinization indicated by a serum progesterone above 2 ng/mL.</paragraph>
                        <paragraph>A multicenter, open-label, randomized study was conducted to assess the efficacy and safety of ganirelix acetate injection in women undergoing COH. Follicular phase treatment with ganirelix acetate 250 mcg was studied using a luteal phase GnRH agonist as a reference treatment. A total of 463 subjects were treated with ganirelix acetate by subcutaneous injection once daily starting on Day 6 of recombinant FSH treatment. Recombinant FSH was maintained at 150 IU for the first 5 days of ovarian stimulation and was then adjusted by the investigator on the sixth day of gonadotropin use according to individual responses. The results for the ganirelix acetate arm are summarized in Table 3.</paragraph>
                        <table ID="ID15" width="0" styleCode="Noautorules">
                           <caption>  Table 3: Results from the Multicenter, Open-label, Randomized Study to Assess the Efficacy and Safety of Ganirelix Acetate Injection in Women Undergoing COH </caption>
                           <col width="293"/>
                           <col width="288"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2">
                                    <paragraph styleCode="Footnote">
                                       <content styleCode="italics">(Protocol 38607)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Ganirelix Acetate 250 mcg</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. subjects treated<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 463<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Duration of GnRH analog (days)<sup>§, </sup>
                                    <footnote ID="ID150">Mean (standard deviation)</footnote>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5.4 (2)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Duration of recombinant FSH (days)<sup>§, </sup>
                                    <footnoteRef IDREF="ID150"/>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 9.6 (2)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Serum E<sub>2</sub> (pg/mL) on day of hCG<footnote ID="ID151">Median values</footnote>
                                    <br/> 5<sup>th </sup>to 95<sup>th</sup> percentiles<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1190<br/> 373 to 3105<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Serum LH (mIU/mL) on day of hCG<footnoteRef IDREF="ID151"/>
                                    <br/> 5<sup>th</sup> to 95<sup>th</sup> percentiles<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.6<br/> 0.6 to 6.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. of subjects with LH rise ≥ 10 mIU/mL<footnote ID="ID152">Following initiation of ganirelix acetate therapy</footnote>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. of follicles &gt; 11 mm<sup>§, </sup>
                                    <footnoteRef IDREF="ID150"/>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10.7 (5.3)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. of subjects with oocyte retrieval<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 440<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. of oocytes<footnoteRef IDREF="ID150"/>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.7 (5.6)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Fertilization rate<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 62.1%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. subjects with ET<footnote ID="ID153">ET: Embryo Transfer</footnote>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 399<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. of embryos transferred<footnoteRef IDREF="ID150"/>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.2 (0.6)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> No. of embryos<footnoteRef IDREF="ID150"/>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (4.5)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ongoing pregnancy rate <footnote ID="ID154">As evidenced by ultrasound at 12 to 16 weeks following ET</footnote>
                                    <sup>, </sup>
                                    <footnote ID="ID155">Restricted to subjects with hCG injection</footnote>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> per attempt, n (%)<footnote ID="ID156">
                                       <sup/>Includes one patient who achieved pregnancy with intrauterine induction</footnote>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 94 (20.3)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> per transfer, n (%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 93 (23.3)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Implantation rate (%)<footnoteRef IDREF="ID150"/>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 15.7 (29)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID16">Some centers were limited to the transfer of ≤ 2 embryos based on local practice standards</paragraph>
                        <paragraph>The mean number of days of ganirelix acetate treatment was 5.4 (2 to 14). </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">LH Surges</content>
                           </content>
                        </paragraph>
                        <paragraph>The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. In 463 subjects administered ganirelix acetate injection   250 mcg, a premature LH surge prior to hCG administration, (LH rise ≥ 10 mIU/mL with a significant rise in serum progesterone &gt; 2 ng/mL, or a significant decline in serum estradiol) occurred in less than 1% of subjects.</paragraph>
                     </text>
                     <effectiveTime value="20241016"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID17">
               <id root="89a43c30-0e60-4eda-9be2-90860580a429"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID18">Ganirelix acetate injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.</paragraph>
               </text>
               <effectiveTime value="20240220"/>
            </section>
         </component>
         <component>
            <section ID="ID19">
               <id root="26e52bb4-27b1-4984-9621-be4fccf99c74"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID20">Ganirelix acetate injection is contraindicated under the following conditions:</paragraph>
                  <list listType="unordered" ID="ID21" styleCode="Disc">
                     <item>Known hypersensitivity to ganirelix acetate or to any of its components.</item>
                     <item>Known hypersensitivity to GnRH or any other GnRH analog.</item>
                     <item>Known or suspected pregnancy (see <content styleCode="bold">
                           <linkHtml href="#ID24">PRECAUTIONS</linkHtml>
                        </content> ).</item>
                  </list>
               </text>
               <effectiveTime value="20240619"/>
            </section>
         </component>
         <component>
            <section ID="ID22">
               <id root="3986c212-8faa-495f-881a-272ddcfa4739"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph ID="ID23">Ganirelix acetate injection should be prescribed by physicians who are experienced in infertility treatment. Before starting treatment with ganirelix acetate, pregnancy must be excluded. Safe use of ganirelix acetate during pregnancy has not been established (see <content styleCode="bold">
                        <linkHtml href="#ID19">CONTRAINDICATIONS</linkHtml>
                     </content> and <content styleCode="bold">
                        <linkHtml href="#ID24">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20210401"/>
            </section>
         </component>
         <component>
            <section ID="ID24">
               <id root="6d6e5c77-fe73-4db4-b19f-684561391d06"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20240619"/>
               <component>
                  <section ID="ID25">
                     <id root="e674d122-d86b-458e-b9c6-4cde1af489ef"/>
                     <title>General</title>
                     <text>
                        <paragraph ID="ID26">Special care should be taken in women with signs and symptoms of active allergic conditions. Cases of hypersensitivity reactions (both generalized and local), including anaphylaxis (including anaphylactic shock), angioedema and urticaria, have been reported with ganirelix acetate, as early as with the first dose, during post-marketing surveillance (see <content styleCode="bold">
                              <linkHtml href="#ID41">ADVERSE REACTIONS</linkHtml>
                           </content>). If a hypersensitivity reaction is suspected, ganirelix acetate should be discontinued and appropriate treatment administered. In the absence of clinical experience, ganirelix acetate treatment is not advised in women with severe allergic conditions.</paragraph>
                     </text>
                     <effectiveTime value="20240619"/>
                  </section>
               </component>
               <component>
                  <section ID="ID27">
                     <id root="62ce61d5-f7be-426d-a6a1-478321017c7e"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph ID="ID28">Prior to therapy with ganirelix acetate injection, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see <content styleCode="bold">
                              <linkHtml href="#ID41">ADVERSE REACTIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Ganirelix acetate should not be prescribed if the patient is pregnant.</paragraph>
                     </text>
                     <effectiveTime value="20210401"/>
                  </section>
               </component>
               <component>
                  <section ID="ID29">
                     <id root="75e5b40e-7d77-4b63-aa68-4a4e2ecb9243"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph ID="ID30">A neutrophil count ≥ 8.3 (x 10<sup>9</sup>/L) was noted in 11.9% (up to 16.8 x 10<sup>9</sup>/L) of all subjects treated within the adequate and well-controlled clinical trials. In addition, downward shifts within the ganirelix acetate injection group were observed for hematocrit and total bilirubin. The clinical significance of these findings was not determined.</paragraph>
                     </text>
                     <effectiveTime value="20210401"/>
                  </section>
               </component>
               <component>
                  <section ID="ID31">
                     <id root="194efc36-7539-4da6-85ea-c2405d3f130f"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph ID="ID32">No formal drug-drug interaction studies have been performed.</paragraph>
                     </text>
                     <effectiveTime value="20210401"/>
                  </section>
               </component>
               <component>
                  <section ID="ID33">
                     <id root="d1199205-742a-4011-9b22-ed5f73a4bc7e"/>
                     <title>Carcinogenesis and Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID34">Long-term toxicity studies in animals have not been performed with ganirelix acetate injection to evaluate the carcinogenic potential of the drug. Ganirelix acetate did not induce a mutagenic response in the Ames test <content styleCode="italics">(S. typhimurium </content>and <content styleCode="italics">E. coli</content>) or produce chromosomal aberrations in <content styleCode="italics">in vitro </content>assay using Chinese Hamster Ovary cells.</paragraph>
                     </text>
                     <effectiveTime value="20210401"/>
                  </section>
               </component>
               <component>
                  <section ID="ID35">
                     <id root="7136816b-ecb2-40a6-8083-6b36ce1030b5"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph ID="ID36">Ganirelix acetate injection is contraindicated in pregnant women. When administered from Day 7 to near term to pregnant rats and rabbits at doses up to 10 and 30 mcg/day (approximately 0.4 to 3.2 times the human dose based on body surface area), ganirelix acetate increased the incidence of litter resorption. There was no increase in fetal abnormalities. No treatment-related changes in fertility, physical, or behavioral characteristics were observed in the offspring of female rats treated with ganirelix acetate during pregnancy and lactation.</paragraph>
                        <paragraph>The effects on fetal resorption are logical consequences of the alteration in hormonal levels brought about by the antigonadotropic properties of this drug and could result in fetal loss in humans. Therefore, this drug should not be used in pregnant women (see <content styleCode="bold">
                              <linkHtml href="#ID19">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20230823"/>
                  </section>
               </component>
               <component>
                  <section ID="ID37">
                     <id root="d0418851-33b7-43f5-8a96-70a6d5906b77"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph ID="ID38">Ganirelix acetate injection should not be used by lactating women. It is not known whether this drug is excreted in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20210401"/>
                  </section>
               </component>
               <component>
                  <section ID="ID39">
                     <id root="a2a1be8d-6c0f-481b-9590-d1c6f5a91da9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph ID="ID40">Clinical studies with ganirelix acetate injection did not include a sufficient number of subjects aged 65 and over.</paragraph>
                     </text>
                     <effectiveTime value="20210401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID41">
               <id root="e900d98a-c4ef-436e-85fb-3f16ffee86ad"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID42">The safety of ganirelix acetate injection was evaluated in two randomized, parallel-group, multicenter controlled clinical studies. Treatment duration for ganirelix acetate ranged from 1 to 14 days. Table 4 represents adverse events (AEs) from first day of ganirelix acetate administration until confirmation of pregnancy by ultrasound at an incidence of ≥ 1% in ganirelix acetate-treated subjects without regard to causality.</paragraph>
                  <table ID="ID43" width="605" styleCode="Noautorules">
                     <caption>  Table 4: Incidence of Common Adverse Events (Incidence ≥ 1% in Ganirelix Acetate-treated Subjects). Completed Controlled Clinical Studies (All-subjects-treated Group) </caption>
                     <col width="311"/>
                     <col width="294"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Adverse Events Occurring in </content>
                              <content styleCode="bold"> ≥ 1%</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Ganirelix Acetate </content>
                              <br/>
                              <content styleCode="bold"> N=794</content>
                              <br/>
                              <content styleCode="bold"> % (n)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain (gynecological)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 4.8 (38)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Death Fetal<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.7 (29)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 (24)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ovarian Hyperstimulation Syndrome<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.4 (19)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Vaginal Bleeding<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.8 (14)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Injection Site Reaction<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 (9)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nausea<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 (9)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain (gastrointestinal)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (8)<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID44">During post-marketing surveillance, rare cases of hypersensitivity reactions, including anaphylaxis (including anaphylactic shock), angioedema and urticaria have been reported with ganirelix acetate, as early as with the first dose (see <content styleCode="bold">
                        <linkHtml href="#ID24">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Congenital Anomalies</content>
                     </content>
                  </paragraph>
                  <paragraph>An observational study in more than 1000 newborns compared the incidence of congenital anomalies in newborns of women administered ganirelix acetate to historical controls of a GnRH agonist. This study demonstrated that the incidence of congenital anomalies in children born after COH treatment in women using ganirelix acetate was comparable with that reported after a COH treatment cycle using a GnRH agonist.</paragraph>
                  <paragraph>The incidence of congenital malformations after some Assisted Reproductive Technologies (ART) [specifically <content styleCode="italics">in vitro</content> fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI. The causal relationship between these congenital anomalies and ganirelix acetate injection is unknown.</paragraph>
               </text>
               <effectiveTime value="20241025"/>
            </section>
         </component>
         <component>
            <section ID="ID45">
               <id root="834c43f4-067a-4cbc-963c-b91f213bf268"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID46">There have been no reports of overdosage with ganirelix acetate injection in humans.</paragraph>
               </text>
               <effectiveTime value="20210401"/>
            </section>
         </component>
         <component>
            <section ID="ID47">
               <id root="5f005132-2a78-4fc2-80dc-dda519e79ccc"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="ID48">After initiating FSH therapy on Day 2 or 3 of the cycle, ganirelix acetate injection 250 mcg may be administered subcutaneously once daily during the mid to late portion of the follicular phase. By taking advantage of endogenous pituitary FSH secretion, the requirement for exogenously administered FSH may be reduced. Treatment with ganirelix acetate should be continued daily until the day of hCG administration. When a sufficient number of follicles of adequate size are present, as assessed by ultrasound, final maturation of follicles is induced by administering hCG. The administration of hCG should be withheld in cases where the ovaries are abnormally enlarged on the last day of FSH therapy to reduce the chance of developing OHSS (Ovarian Hyperstimulation Syndrome).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Directions for Using Ganirelix Acetate Injection</content>
                  </paragraph>
                  <list listType="ordered" ID="ID49">
                     <item>Ganirelix acetate injection is supplied in a single dose, sterile, prefilled syringe and is intended for SUBCUTANEOUS administration only.</item>
                     <item>Air bubble(s) may be seen in the pre-filled syringe. This is expected, and removal of the air bubble(s) is not needed.</item>
                     <item>Wash hands thoroughly with soap and water.</item>
                     <item>The most convenient sites for SUBCUTANEOUS injection are in the abdomen around the navel or upper thigh.</item>
                     <item>The injection site should be swabbed with a disinfectant to remove any surface bacteria. Clean about two inches around the point where the needle will be inserted and let the disinfectant dry for at least one minute before proceeding.</item>
                     <item>With syringe held upward, remove needle cover.</item>
                     <item>Pinch up a large area of skin between the finger and thumb. Vary the injection site a little with each injection.</item>
                     <item>The needle should be inserted at the base of the pinched-up skin at an angle of 45 to 90° to the skin surface.</item>
                     <item>When the needle is correctly positioned, it will be difficult to draw back on the plunger. If any blood is drawn into the syringe, the needle tip has penetrated a vein or artery. If this happens, withdraw the needle slightly and reposition the needle without removing it from the skin. Alternatively, remove the needle and use a new, sterile, prefilled syringe. Cover the injection site with a swab containing disinfectant and apply pressure; the site should stop bleeding within one or two minutes.</item>
                     <item>Once the needle is correctly placed, depress the plunger slowly and steadily, so the solution is correctly injected and the skin is not damaged.</item>
                     <item>Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant.</item>
                     <item>Use the sterile, prefilled syringe only once. Discard the unused portion and dispose of it properly.</item>
                  </list>
               </text>
               <effectiveTime value="20230823"/>
            </section>
         </component>
         <component>
            <section ID="ID50">
               <id root="b97a3c6e-9e53-4fdc-ad9a-44520ef94e2c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph ID="ID51">Ganirelix acetate injection is supplied in:</paragraph>
                  <paragraph>Disposable, ready for use, single dose, sterile, prefilled 1 mL glass syringes containing 250 mcg/0.5 mL aqueous solution of ganirelix acetate closed with a rubber piston that does not contain latex. Each ganirelix acetate sterile, prefilled syringe is affixed with a 27 gauge x   1/2-inch needle closed by a needle shield that does not contain latex. </paragraph>
                  <paragraph>Single syringe                                   NDC 70748-274-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light.</paragraph>
                  <paragraph>The brands listed are trademarks of their respective owners and are not trademarks of Lupin Pharmaceuticals, Inc. The makers of these brands are not affiliated with and do not endorse Lupin Pharmaceuticals, Inc. or its products.</paragraph>
                  <paragraph>LUPIN and the  <renderMultiMedia referencedObject="IMGID511"/>are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Nagpur 441 108</paragraph>
                  <paragraph>INDIA</paragraph>
                  <paragraph>October 2024                                                                                                                 #ID: 276316</paragraph>
               </text>
               <effectiveTime value="20241017"/>
               <component>
                  <observationMedia ID="IMGID511">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="6b562339-0c67-41b1-81ef-5a4e89721353-51-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID56">
               <id root="611f3d6a-e0af-4e0d-8a23-18cb98c32611"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID57">NDC 70748-274-01</paragraph>
                  <paragraph>Ganirelix Acetate Injection </paragraph>
                  <paragraph>250 mcg/0.5 mL </paragraph>
                  <paragraph>Container label of 250 mcg Single-dose Sterile Prefilled Syringe</paragraph>
                  <paragraph>27 gauge by 1/2" needle</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID59">NDC 70748-274-01</paragraph>
                  <paragraph>Ganirelix Acetate Injection </paragraph>
                  <paragraph>250 mcg/0.5 mL </paragraph>
                  <paragraph>Carton label of 250 mcg Single-dose Sterile Prefilled Syringe</paragraph>
                  <paragraph>27 gauge by 1/2" needle</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>container label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="2c0284c8-3a82-4bb9-a486-a03fc1491c66-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="2c0284c8-3a82-4bb9-a486-a03fc1491c66-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>